Zoetis Inc. (NYSE:ZTS) is AAFMAA Wealth Management & Trust LLC’s 7th Largest Position

AAFMAA Wealth Management & Trust LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 31,262 shares of the company’s stock after selling 2,477 shares during the quarter. Zoetis accounts for about 2.9% of AAFMAA Wealth Management & Trust LLC’s portfolio, making the stock its 7th largest holding. AAFMAA Wealth Management & Trust LLC’s holdings in Zoetis were worth $5,290,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. AQR Capital Management LLC grew its stake in shares of Zoetis by 52.3% during the 3rd quarter. AQR Capital Management LLC now owns 66,328 shares of the company’s stock worth $11,540,000 after purchasing an additional 22,779 shares during the period. Lido Advisors LLC grew its stake in shares of Zoetis by 3.4% during the 3rd quarter. Lido Advisors LLC now owns 8,828 shares of the company’s stock worth $1,536,000 after purchasing an additional 288 shares during the period. GSA Capital Partners LLP grew its stake in shares of Zoetis by 102.1% during the 3rd quarter. GSA Capital Partners LLP now owns 7,827 shares of the company’s stock worth $1,362,000 after purchasing an additional 3,954 shares during the period. Ramirez Asset Management Inc. acquired a new stake in shares of Zoetis during the 3rd quarter worth approximately $35,000. Finally, Essex Financial Services Inc. grew its stake in shares of Zoetis by 12.5% during the 3rd quarter. Essex Financial Services Inc. now owns 2,102 shares of the company’s stock worth $366,000 after purchasing an additional 233 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.3 %

NYSE ZTS traded up $0.49 during trading on Monday, hitting $175.45. The stock had a trading volume of 1,704,730 shares, compared to its average volume of 2,923,235. The company has a market capitalization of $80.06 billion, a PE ratio of 33.90, a PEG ratio of 2.72 and a beta of 0.86. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. The firm has a 50 day moving average price of $171.00 and a 200 day moving average price of $177.80. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. The company had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. Zoetis’s revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.31 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 5.76 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio is presently 33.33%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ZTS shares. Barclays dropped their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. HSBC dropped their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus dropped their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Finally, The Goldman Sachs Group decreased their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $211.75.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at $2,237,316. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.